Bristol Myers Squibb
-
Actualités
FDA Grants Priority Review to Luspatercept-aamt for Anemia in Adults With NTD β-Thalassaemia
The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 27, 2022. In addition, the European Medicines Agency (EMA) has validated the Type II variation…
Lire la suite » -
Actualités
New Paper From Blood and Beyond Outlines How To Learn From The Impact Of The COVID-19 Crisis On Blood Use
The multi-stakeholder Blood and Beyond initiative recently published a policy briefing shedding light on how the COVID-19 pandemic affects blood use, blood transfusion services, and patients in whom transfusions are…
Lire la suite »